Coinbase CEO's Start-Up NewLimit Raises $40 Million to Increase Human Lifespan
NewLimit, a startup co-founded by crypto exchange giant Coinbase CEO Brian Armstrong, has raised $40 million with a goal to add years to people's lives.
This longevity pharma startup, co-founded by former Google Ventures partner with a Stanford Ph.D. in bioengineering, Blake Byers, announced the Series A funding on Tuesday from investors including Dimension, Founders Fund, Kleiner Perkins, Eric Schmidt, Elad Gil, Garry Tan, and Fred Ehrsam.
In 2021, the company raised $110 million from Byers and Armstrong. This money is committed over the lifetime of the company, the two told TechCrunch, so it’s not fully funded yet.
The latest $40 million is a commitment from VCs, also to be accessed over time, not funds given at once.
There is no talk of valuation yet, the two added.
The four co-founders also include Greg Johnson, who formerly led the development of novel machine learning methods at the Allen Institute for Cell Science, and Jacob Kimmel, who led a research laboratory focused on epigenetic reprogramming as a Principal Investigator and Computational Fellow at research and development company Calico.
"Greg [Johnson] and Jacob [Kimmel] are really operating the business day to day," Armstrong told TechCrunch, adding that he himself is "really just an investor and a board member."
The company at the moment has no CEO, with Byers and Armstrong saying that it is in an early stage and the founding team is working well in its current form.
According to the latest press release, NewLimit was founded to "cure aging" via "epigenetic reprogramming," aiming to "figure out a way to restore the regenerative potential we all had when we were younger, but somehow lost."
NewLimit wants to research epigenetic drivers of aging and develop
Read more on cryptonews.com
